Publications by authors named "S Suekane"
(Purpose) Enfortumab vedotin has been available as a third-line treatment for advanced urothelial carcinoma in Japan since December 2021. While the treatment is expected to improve the outcome of advanced urothelial carcinoma, concerns regarding adverse events do exist. We report here our initial experience of the use of enfortumab vedotin as a third-line therapy in patients with advanced urothelial carcinoma.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated the effectiveness and safety of nivolumab and ipilimumab (NIVO+IPI) in elderly patients over 75 years with advanced renal cell carcinoma (RCC).
- It involved 59 patients and compared treatment outcomes, such as response rates and survival, between those younger and older than 75.
- Findings indicated no major differences in treatment effectiveness or severe side effects, but older patients showed better overall survival compared to younger ones.
Objectives: Desmopressin improves nocturia frequency; however, reports on its long-term efficacy and safety are few, and concerns regarding its effect on body composition exist. We thus investigated the efficacy and safety of long-term desmopressin administration and its effect on body composition.
Methods: This retrospective study, conducted at Chikugo City Hospital between August 2020 and December 2022, involved 133 men (mean age, 77.
Article Synopsis
- A multicenter study in Japan analyzed 515 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) to determine the best PSA doubling time (PSADT) cut-off for prognosis.
- The study found that a PSADT of less than 4.65 months is a significant predictor for overall survival (OS) and cancer-specific survival (CSS), indicating worse outcomes.
- Patients receiving novel hormonal therapy (NHT) had better progression-free survival (PFS) compared to those on older treatments, highlighting the benefits of newer treatment options.
Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the expression of soluble immune checkpoint molecules and the therapeutic efficacy of IO combination therapy in advanced RCC.
View Article and Find Full Text PDF